Ofloxavis (Ofloxacin)

Ofloxacin belongs to the fluoroquinolone class and works by inhibiting bacterial DNA gyrase and topoisomerase IV. These enzymes are essential for DNA replication and transcription, so their blockade leads to bacterial cell death and helps clear the infection from the ocular surface.

The dosing regimen for Ofloxavis is determined by the prescribing eye‑care professional based on the specific infection, severity, and patient age. The prescriber will provide exact instructions on the number of drops, frequency, and duration of therapy.

Safety data for ocular ofloxacin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To request Ofloxavis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ofloxavis (ofloxacin) offers broad‑spectrum coverage against Gram‑negative and Gram‑positive bacteria, similar to other fluoroquinolone eye drops such as ciprofloxacin. Compared with macrolide or aminoglycoside ophthalmic agents, ofloxacin generally provides faster bacterial eradication and a convenient dosing schedule, but the choice depends on local resistance patterns and patient tolerance.

Store Ofloxavis at room temperature, preferably below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and avoid freezing. Do not refrigerate unless specifically instructed by the supplier.

The eye drops are instilled directly onto the affected eye(s) as directed by the prescriber, typically one to two drops per dose. Patients should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and follow the prescribed frequency and duration.

Serious adverse reactions, although rare, include severe allergic responses such as eyelid swelling, rash, hives, or anaphylaxis, as well as corneal ulceration or perforation that can threaten vision. Any sudden increase in eye pain, loss of vision, or signs of a severe reaction should prompt immediate medical attention.

Ofloxavis should be avoided in patients with a known hypersensitivity to fluoroquinolones or any excipients in the formulation. It is also contraindicated in eyes with perforated corneas, severe epithelial defects, or in individuals where the risk of tendon disorders is heightened due to systemic fluoroquinolone exposure.